Regenron Updated Data Demonstrated Strong Response in Multiple Myeloma

 71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow-up

Data to be submitted to regulatory authorities, with Biologics License Application on track to be submitted to the FDA this year

Regeneron to host virtual investor event to discuss results alongside updates across its hematology portfolio on Thursday, December 14 at 8:30 a.m. ET

https://www.globenewswire.com/news-release/2023/12/07/2792394/0/en/Updated-Linvoseltamab-Pivotal-Data-Demonstrated-Strong-Rates-and-Depth-of-Response-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma.html